Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action
作者:Xingchun Han、Chengang Zhou、Min Jiang、Yongguang Wang、Jianhua Wang、Zhanling Cheng、Min Wang、Yongqiang Liu、Chungen Liang、Jianping Wang、Zhanguo Wang、Robert Weikert、Wenzhe Lv、Jianxun Xie、Xin Yu、Xue Zhou、Souphalone Luangsay、Hong C. Shen、Alexander V. Mayweg、Hassan Javanbakht、Song Yang
DOI:10.1021/acs.jmedchem.8b01245
日期:2018.12.13
orally bioavailable HBV inhibitor which can reduce both viral antigens and viral DNA with a novel mechanism of action. Here we report the discovery of RG7834 from a phenotypic screening and the structure–activity relationship (SAR) of the DHQ chemical series. RG7834 can selectively inhibit HBV but not other DNA or RNA viruses in a virus panel screening. Both in vitro and in vivo profiles of RG7834 are described
慢性乙型肝炎病毒(HBV)感染是严重的公共健康负担,当前的疗法无法达到令人满意的治愈率。具有不同于当前护理标准的作用机理(MOA)的新型治疗剂对医疗的需求很高。RG7834是二氢喹啉嗪酮(DHQ)化学系列的化合物,是一流的高选择性且口服可生物利用的HBV抑制剂,它可以通过一种新颖的作用机理同时降低病毒抗原和病毒DNA。在这里,我们从表型筛选和DHQ化学系列的结构-活性关系(SAR)中报告了RG7834的发现。在病毒组筛选中,RG7834可以选择性抑制HBV,但不能抑制其他DNA或RNA病毒。本文描述了RG7834的体外和体内特性,